Skip to main content
Premium Trial:

Request an Annual Quote

Acquisitive Invitrogen is at it Again

NEW YORK, May 25 (GenomeWeb News) - Invitrogen, with two acquisitions already under its belt this year, has done it again.

The Carlsbad, Calif.-based company has purchased the assets of microarray maker Xeotron of Houston, Texas, for an undisclosed sum, the company confirmed today.

Invitrogen is an aggregator of life science companies that produce and sell reagents and tools, and is armed with some $890 million in cash and investments.

The purchase follows the  April purchase of protein microarray maker Protometrix of Branford, Conn., also for an undisclosed sum, and the $403 million purchase in  February of BioReliance, a Rockville, Md.-based contract service organization.

For details, see 
BioArray News.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.